ArticleOncoTargets and therapy2017
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03587129 (Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Who cites it
12 citing papers in PubMed.
- Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report.World journal of clinical cases · 2022Article
- Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.Journal of ovarian research · 2021Article
- Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.Oxidative medicine and cellular longevity · 2020Article
- Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study.Oncology research · 2019Article
- Sevoflurane Inhibits Proliferation and Invasion of Human Ovarian Cancer Cells by Regulating JNK and p38 MAPK Signaling Pathway.Drug design, development and therapy · 2019Article
- Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.Medicine · 2018Article
- Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review.Oncotarget · 2018Article
- Article
- Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis.OncoTargets and therapy · 2018Review
- Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.Cancer biology & therapy · 2018Review
- Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient's progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.